DIMENSION®

Description of Event or Problem

THE CUSTOMER INFORMED SIEMENS OF IMPRECISE ELEVATED QUALITY CONTROL (QC) RESULTS FOR TACROLIMUS (TAC) WITH LOT: GA2286 ON A DIMENSION EXL 200 SYSTEM. THERE IS NO INDICATION OF PATIENT RESULTS REPORTED WITH QC OUT OF RANGE. THERE IS NO INDICATION OF DELAY OF PATIENT RESULT REPORTING. THERE IS NO INDICATION THAT PATIENT TREATMENT WAS ALTERED, PRESCRIBED OR DELAYED ON THE BASIS OF IMPRECISE TAC QUALITY CONTROL RESULTS.

Additional Manufacturer Narrative

AN OUTSIDE OF UNITED STATES (OUS) CUSTOMER CONTACTED THE SIEMENS HEALTHCARE DIAGNOSTICS REMOTE SERVICES CENTER (RSC) REGARDING IMPRECISION FOR QUALITY CONTROL (QC) SAMPLES WITH DIMENSION TACROLIMUS (TAC) LOT: GA2286 ON A DIMENSION EXL 200 SYSTEM. NO PATIENT SAMPLES WERE IMPACTED BY THIS ISSUE. SIEMENS HEALTHCARE DIAGNOSTICS CONCLUDED THE INVESTIGATION OF THE EVENT. SIEMENS CONFIRMED IMPRECISION FOR QUALITY CONTROL (QC) AND PATIENT SAMPLES WITH DIMENSION TACROLIMUS (TAC) LOTS: GA2286, GA3047 AND GA3171. URGENT MEDICAL DEVICE CORRECTION (UMDC) DC-23-03.A. US DATED 30-JAN-2023 WAS SENT TO ALL UNITED STATES (US) CUSTOMERS WHO HAD BEEN SHIPPED THE IMPACTED LOTS. URGENT FIELD SAFETY NOTICE (UFSN) DC-23-03.A.OUS DATED JANUARY 2023 WAS SENT TO OUTSIDE THE US (OUS) CUSTOMERS WHO HAD BEEN SHIPPED THE IMPACTED LOTS. CUSTOMERS WERE ADVISED TO DISCONTINUE USE AND DISCARD THE DIMENSION TACROLIMUS LOTS: GA2286, GA3047 AND GA3171. ROOT CAUSE INVESTIGATION IS IN PROGRESS AND CORRECTIVE ACTION UPDATES WILL BE PROVIDED IN MONTHLY STATUS UPDATE REPORTS TO THE FDA AS PER 21 CFR PART 806.10.